Novavax CEO: Avian Flu Results Very Positive for Vaccine Maker
Novavax recent positive avian flu results demonstrate the company can make vaccines quickly and for a wide range of viruses including Ebola, said the company's CEO Stanley Erck.
Novavax's recent positive avian flu results demonstrate the company can make vaccines quickly and for a wide range of viruses including Ebola, said the company's CEO Stanley Erck. Erck added that the results show Novavax is on the pathway to a licensed product that will be able to combat future pandemic breakouts. He also said that the company has expanded its deal with the Department of Health and Human Services which will enable it to build infrastructure to develop vaccines. Finally, Erck said the company has over $200 million on its balance sheet to spend on clinical trials of its RSV Vaccine for healthy women in the third trimester of pregnancy.
